A small comparative trial reported similar withdrawal-score improvement among completers. Its handling of complicated withdrawal limits claims of equivalent protection against severe outcomes.
Sixty-six patients were enrolled in baclofen and lorazepam groups. One participant in each group developed delirium on day two and was removed from the final efficacy analysis for standard management. Sixty-four completed the detoxification comparison.
Withdrawal scores and monitored vital signs improved without a significant group difference. Nearly half of baclofen completers also required zolpidem for sleep.
Excluding participants after a serious clinical development changes the population behind the final result. It cannot demonstrate that either treatment prevented delirium or was sufficient for all enrolled patients. Additional hypnotic exposure also qualifies a description of baclofen alone.
The small sample and limitations in blinding and center selection restrict equivalence and rare-event conclusions. Similar symptom scores do not establish identical anticonvulsant protection.
Report both the enrolled group and the analyzed completers. This paper supports a limited symptom comparison; it cannot establish that baclofen can universally replace benzodiazepines or that a different regimen would have prevented an individual alcohol-withdrawal complication.
Original analysis of the supplied journal article, identified as PMC6341928.